Other adverse events: any serious adverse event ‐ short and long term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Death ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes adverse events: extrapyramidal adverse effects dystonia ‐ short term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Service use and hospitalisation: admission ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state: Change over time ‐ no better or deterioration ‐ short and medium term as defined in each study · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes global state: Change over time ‐ no better or deterioration ‐ short… compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mental state: State ‐ 'no effect' BPRS score reduction · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes mental state: State ‐ 'no effect' BPRS score reduction compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review